PRAX · Praxis Precision Medicines, Inc.

Praxis Precision Medicines' announcement of FDA acceptance for its New Drug Application (NDA) for ulixacaltamide HCl represents a critical regulatory milestone for the treatment of essential tremor in adults. The Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027 provides a clear timeline for potential approval, enabling investors to gauge commercialization prospects. The decision not to hold an advisory committee meeting suggests the FDA views the application without significant unresolved safety or efficacy concerns requiring external expert input, potentially streamlining the review process. This development advances Praxis' pipeline, positioning ulixacaltamide HCl as a candidate for market entry in a neurology-focused therapeutic area, with implications for future revenue generation upon approval.